CL2017001090A1 - Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción - Google Patents
Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producciónInfo
- Publication number
- CL2017001090A1 CL2017001090A1 CL2017001090A CL2017001090A CL2017001090A1 CL 2017001090 A1 CL2017001090 A1 CL 2017001090A1 CL 2017001090 A CL2017001090 A CL 2017001090A CL 2017001090 A CL2017001090 A CL 2017001090A CL 2017001090 A1 CL2017001090 A1 CL 2017001090A1
- Authority
- CL
- Chile
- Prior art keywords
- redirection
- cells
- production methods
- heterodimeric immunoglobulins
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2014/073738 WO2015063339A1 (fr) | 2013-11-04 | 2014-11-04 | Production de cellules t reciblant des immunoglobulines héréro-dimériques |
| EP15167034 | 2015-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001090A1 true CL2017001090A1 (es) | 2018-01-05 |
Family
ID=53059011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001090A CL2017001090A1 (es) | 2014-11-04 | 2017-05-02 | Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP3215541A1 (fr) |
| JP (3) | JP2018501297A (fr) |
| KR (1) | KR102760422B1 (fr) |
| CN (1) | CN107207596A (fr) |
| AU (1) | AU2015341884B2 (fr) |
| BR (1) | BR112017009263A2 (fr) |
| CA (1) | CA2965745C (fr) |
| CL (1) | CL2017001090A1 (fr) |
| CO (1) | CO2017005240A2 (fr) |
| EA (1) | EA039658B1 (fr) |
| HK (1) | HK1244014A1 (fr) |
| IL (1) | IL251848A0 (fr) |
| MA (1) | MA40894A (fr) |
| MX (1) | MX2017005814A (fr) |
| MY (1) | MY186929A (fr) |
| NZ (1) | NZ732019A (fr) |
| PE (1) | PE20171041A1 (fr) |
| PH (1) | PH12017500819A1 (fr) |
| SG (1) | SG11201703313SA (fr) |
| WO (1) | WO2016071355A1 (fr) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11434302B2 (en) | 2016-02-03 | 2022-09-06 | Amgen Research (Munich) Gmbh | Bispecific T cell engaging antibody constructs |
| US11447567B2 (en) | 2015-07-31 | 2022-09-20 | Amgen Research (Munich) Gmbh | Antibody constructs for FLT3 and CD3 |
| US11884720B2 (en) | 2015-07-31 | 2024-01-30 | Amgen Research (Munich) Gmbh | Antibody constructs for MSLN and CD3 |
| US12428491B2 (en) | 2016-02-03 | 2025-09-30 | Amgen Research (Munich) Gmbh | PSMA and CD3 bispecific T cell engaging antibody constructs |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| KR102391731B1 (ko) | 2013-01-14 | 2022-04-27 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| JP6693872B2 (ja) | 2013-07-25 | 2020-05-13 | シトムクス セラピューティクス，インコーポレイティド | 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法 |
| AP2016009222A0 (en) | 2013-11-04 | 2016-05-31 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
| PL3122781T3 (pl) | 2014-03-28 | 2020-06-15 | Xencor, Inc. | Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3 |
| CA2955947A1 (fr) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anticorps anti-cd3, anticorps anti-cd3 activables, anticorps anti-cd3 multispecifiques, anticorps anti-cd3 activables multispecifiques et procedes d'utilisation de ces anticorps |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| HK1245171A1 (zh) | 2014-11-26 | 2018-08-24 | Xencor, Inc. | 结合cd3和cd38的异二聚体抗体 |
| JP6696982B2 (ja) | 2014-11-26 | 2020-05-20 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３および腫瘍抗原に結合するヘテロ二量体抗体 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| EP3387013B1 (fr) | 2015-12-07 | 2022-06-08 | Xencor, Inc. | Anticorps hétérodimères se liant à cd3 et psma |
| CA3026151A1 (fr) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Anticorps inhibiteurs de points de controle bispecifiques |
| RU2019102008A (ru) | 2016-06-28 | 2020-07-28 | Ксенкор, Инк. | Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа |
| EP3615571A1 (fr) * | 2017-04-24 | 2020-03-04 | Ichnos Sciences SA | Anticorps bispécifiques de redirection de lymphocytes t pour le traitement de cancers positifs de l'egfr |
| US11319371B2 (en) | 2017-06-05 | 2022-05-03 | Numab Therapeutics AG | Anti-CD3 antibodies |
| WO2018224441A1 (fr) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Nouveaux anticorps anti-cd3 |
| KR102770106B1 (ko) * | 2017-06-08 | 2025-02-21 | 블랙 벨트 테라퓨틱스 리미티드 | Cd38 조정 항체 |
| US11780930B2 (en) | 2017-06-08 | 2023-10-10 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| BR112020002636A2 (pt) | 2017-08-10 | 2020-07-28 | Grifols Diagnostic Solutions Inc. | composições, métodos e/ou kits que compreendem um domínio extracelular recombinante de cd38 humano |
| JP7299873B2 (ja) | 2017-08-16 | 2023-06-28 | ブラック ベルト セラピューティクス リミテッド | Ｃｄ３８抗体 |
| US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| WO2019035938A1 (fr) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Molécules multispécifiques se liant à bcma et leurs utilisations |
| AU2018316521B2 (en) | 2017-08-16 | 2025-01-30 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| CN111247171A (zh) | 2017-10-14 | 2020-06-05 | 西托姆克斯治疗公司 | 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法 |
| AU2018366199A1 (en) | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
| CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
| CA3113756A1 (fr) * | 2018-09-25 | 2020-04-02 | Ichnos Sciences S.A. | Quantification d'anticorps dans des echantillons biologiques |
| KR102353568B1 (ko) * | 2018-11-14 | 2022-01-20 | 주식회사 헬릭스미스 | 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편 |
| CN113614107A (zh) | 2019-01-23 | 2021-11-05 | Encefa公司 | Cd31竞争剂及其用途 |
| WO2020182984A2 (fr) * | 2019-03-13 | 2020-09-17 | Ichnos Sciences SA | Glycosylation sans consensus d'anticorps bispécifiques |
| KR20220012313A (ko) * | 2019-05-23 | 2022-02-03 | 벨로스바이오 인코포레이티드 | 항-ror1/항-cd3 이중특이적 결합 분자 |
| WO2020250940A1 (fr) * | 2019-06-11 | 2020-12-17 | 小野薬品工業株式会社 | Agent d'immunosuppression |
| CN110551222B (zh) * | 2019-08-27 | 2023-06-06 | 重庆市畜牧科学院 | 一种新型双功能抗体及其用途 |
| CN112538114B (zh) * | 2019-09-20 | 2025-05-02 | 上海普铭生物科技有限公司 | 抗人cd38抗体及其应用 |
| TWI841790B (zh) * | 2019-09-30 | 2024-05-11 | 大陸商和鉑醫藥（上海）有限責任公司 | 靶向cd3的抗體、雙特異性抗體及其用途 |
| CR20220330A (es) * | 2019-12-13 | 2022-08-04 | Genentech Inc | Anticuerpos anti-ly6g6d y métodos de uso. |
| CN113493519B (zh) * | 2020-03-19 | 2022-12-27 | 浙江道尔生物科技有限公司 | 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白 |
| WO2021185004A1 (fr) | 2020-03-19 | 2021-09-23 | 深圳纽迪瑞科技开发有限公司 | Appareil de détection de pression et dispositif de détection de pression |
| CN115803340A (zh) * | 2020-04-24 | 2023-03-14 | 纪念斯隆凯特琳癌症中心 | 抗cd3抗体及其用途 |
| EP4149632A1 (fr) | 2020-05-14 | 2023-03-22 | Xencor, Inc. | Anticorps hétérodimères se liant à msln et cd3 |
| WO2021231976A1 (fr) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Anticorps hétérodimères qui se lient à l'antigène membranaire spécifique de la prostate (psma) et cd3 |
| CA3180690A1 (fr) * | 2020-06-17 | 2021-12-23 | Ahmed Mahiuddin | Anticorps anti-cd38 pour le traitement de maladies humaines |
| US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| EP4305067A1 (fr) | 2021-03-09 | 2024-01-17 | Xencor, Inc. | Anticorps hétérodimériques se liant à cd3 et à cldn6 |
| US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
| KR20240040097A (ko) * | 2021-08-04 | 2024-03-27 | 에이비프로 코퍼레이션 | Cd3 표적화 항체 및 이의 용도 |
| CN116724057A (zh) * | 2022-11-28 | 2023-09-08 | 浙江时迈药业有限公司 | 蛋白酶可切割的重组双特异性抗体和组合物及其用途 |
| CN118108852B (zh) * | 2023-11-23 | 2025-11-18 | 浙江大学 | 一种抗啶虫脒单克隆抗体及其重组全长IgG表达质粒 |
| CN120623348B (zh) * | 2025-06-16 | 2026-06-09 | 江苏阿塔斯生物科技有限公司 | 一种抗人cd3兔重组单克隆抗体及其制备方法与应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2915820A1 (fr) * | 2004-02-06 | 2015-09-09 | MorphoSys AG | Anticorps humains anti-CD38 et utilisations de ceux-ci |
| EP2551282A3 (fr) * | 2005-03-23 | 2013-02-13 | Genmab A/S | Anticorps diriges contre CD38 pour le traitement du myelome multiple |
| CN101287764B (zh) * | 2005-10-12 | 2013-11-13 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
| EP1914242A1 (fr) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Nouveau anticorps Anti-CD38 pour le traitement du cancer |
| TWI507525B (zh) * | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| AU2010336277B2 (en) * | 2009-12-25 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide modification method for purifying polypeptide multimers |
| EP2580243B1 (fr) * | 2010-06-09 | 2019-10-16 | Genmab A/S | Anticorps dirigés contre le cd38 humain |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| JP2014511836A (ja) * | 2011-03-25 | 2014-05-19 | グレンマーク ファーマシューティカルズ， エセ．アー． | ヘテロ二量体免疫グロブリン |
| US20150239991A1 (en) * | 2012-09-25 | 2015-08-27 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| US9486547B2 (en) * | 2012-11-05 | 2016-11-08 | Morphosys Ag | Radiolabelled antibody and uses thereof |
| AP2016009222A0 (en) * | 2013-11-04 | 2016-05-31 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
-
2015
- 2015-11-02 MA MA040894A patent/MA40894A/fr unknown
- 2015-11-03 EA EA201790961A patent/EA039658B1/ru unknown
- 2015-11-03 EP EP15790129.9A patent/EP3215541A1/fr not_active Withdrawn
- 2015-11-03 CA CA2965745A patent/CA2965745C/fr active Active
- 2015-11-03 HK HK18103440.0A patent/HK1244014A1/zh unknown
- 2015-11-03 SG SG11201703313SA patent/SG11201703313SA/en unknown
- 2015-11-03 BR BR112017009263-8A patent/BR112017009263A2/pt not_active Application Discontinuation
- 2015-11-03 JP JP2017542319A patent/JP2018501297A/ja active Pending
- 2015-11-03 CN CN201580072196.8A patent/CN107207596A/zh active Pending
- 2015-11-03 AU AU2015341884A patent/AU2015341884B2/en active Active
- 2015-11-03 KR KR1020177015252A patent/KR102760422B1/ko active Active
- 2015-11-03 MX MX2017005814A patent/MX2017005814A/es unknown
- 2015-11-03 WO PCT/EP2015/075628 patent/WO2016071355A1/fr not_active Ceased
- 2015-11-03 PE PE2017000802A patent/PE20171041A1/es unknown
- 2015-11-03 NZ NZ732019A patent/NZ732019A/en unknown
- 2015-11-03 MY MYPI2017701499A patent/MY186929A/en unknown
-
2017
- 2017-04-23 IL IL251848A patent/IL251848A0/en unknown
- 2017-05-02 CL CL2017001090A patent/CL2017001090A1/es unknown
- 2017-05-03 PH PH12017500819A patent/PH12017500819A1/en unknown
- 2017-05-26 CO CONC2017/0005240A patent/CO2017005240A2/es unknown
-
2019
- 2019-07-23 JP JP2019135318A patent/JP2019214582A/ja active Pending
-
2021
- 2021-08-02 JP JP2021126392A patent/JP7403505B2/ja active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11447567B2 (en) | 2015-07-31 | 2022-09-20 | Amgen Research (Munich) Gmbh | Antibody constructs for FLT3 and CD3 |
| US11884720B2 (en) | 2015-07-31 | 2024-01-30 | Amgen Research (Munich) Gmbh | Antibody constructs for MSLN and CD3 |
| US11434302B2 (en) | 2016-02-03 | 2022-09-06 | Amgen Research (Munich) Gmbh | Bispecific T cell engaging antibody constructs |
| US12428491B2 (en) | 2016-02-03 | 2025-09-30 | Amgen Research (Munich) Gmbh | PSMA and CD3 bispecific T cell engaging antibody constructs |
Also Published As
| Publication number | Publication date |
|---|---|
| CO2017005240A2 (es) | 2017-10-31 |
| AU2015341884A1 (en) | 2017-06-08 |
| KR102760422B1 (ko) | 2025-02-03 |
| JP7403505B2 (ja) | 2023-12-22 |
| EA039658B1 (ru) | 2022-02-22 |
| CN107207596A (zh) | 2017-09-26 |
| JP2021184722A (ja) | 2021-12-09 |
| MA40894A (fr) | 2017-09-12 |
| KR20170078831A (ko) | 2017-07-07 |
| SG11201703313SA (en) | 2017-05-30 |
| EP3215541A1 (fr) | 2017-09-13 |
| MY186929A (en) | 2021-08-26 |
| HK1244014A1 (zh) | 2018-07-27 |
| EA201790961A1 (ru) | 2017-10-31 |
| MX2017005814A (es) | 2017-08-02 |
| JP2018501297A (ja) | 2018-01-18 |
| BR112017009263A2 (pt) | 2018-01-30 |
| CA2965745C (fr) | 2023-12-05 |
| IL251848A0 (en) | 2017-06-29 |
| PE20171041A1 (es) | 2017-07-19 |
| JP2019214582A (ja) | 2019-12-19 |
| CA2965745A1 (fr) | 2016-05-12 |
| PH12017500819A1 (en) | 2017-10-02 |
| WO2016071355A1 (fr) | 2016-05-12 |
| AU2015341884B2 (en) | 2020-09-17 |
| NZ732019A (en) | 2022-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017005240A2 (es) | Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción | |
| CY1124993T1 (el) | Ετεροδιμερικα αντισωματα που δεσμευουν cd3 και cd20 | |
| CY1123236T1 (el) | Αντισωματα διπλης εξειδικευσης που δεσμευονται με cd38 και cd3 | |
| MX2021014956A (es) | Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos. | |
| NI201700016A (es) | Conjugados de fármacos con anticuerpos anti-cdh6 | |
| CL2017001361A1 (es) | Anticuerpos heterodiméricos que se unen a cd3 y cd38 | |
| MX2016009555A (es) | Proteinas de union y metodos para utilizarlas. | |
| MX2017014353A (es) | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales. | |
| CO2017006740A2 (es) | Anticuerpos anti–cd79b | |
| UY35399A (es) | Conjugados de fármacos con anticuerpos | |
| EP3186279C0 (fr) | Constructions d'anticorps pour cdh19 et cd3 | |
| MX384364B (es) | Anticuerpos anti-pd-l1 y sus usos de diagnóstico. | |
| UY36905A (es) | Anticuerpos neutralizantes de poliomavirus | |
| JO3791B1 (ar) | تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6 | |
| UY36942A (es) | Proteínas de unión a antígeno que activan el receptor de leptina | |
| CO2018013298A2 (es) | Anticuerpos anti-gitr y sus usos. | |
| CR20170059A (es) | ANTICUERPOS Anti-LAG3 Y FRAGMENTOS DE UNIÓN A ANTÍGENO | |
| EA201691610A1 (ru) | Анти-jagged1 антитела и способы применения | |
| CY1125400T1 (el) | Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων | |
| CL2016001753A1 (es) | Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer | |
| UY37683A (es) | Anticuerpo monoclonal anti-pd-l1 monoclonal | |
| CL2017000212A1 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
| AR101671A1 (es) | Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso | |
| CL2020000920A1 (es) | Anticuerpo monoclonal anti-il-5ra. | |
| BR112018004733A2 (pt) | anticorpos do receptor de transferrina humana/ a-beta anti-humana biespecíficos e métodos de uso |